Business
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera.
About this update from Marizyme, Inc.
[{"type":"text","content":"\n\n\n\nMarizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMarizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera\nPR Newswire\nJUPITER, Fla., March 4, 2021\n\n\n\nJUPITER, Fla., March 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has entered into a supply and distribution agreement with Abdera Financial, Inc., a Chilean based distributor, to distribute Marizyme's DuraGraft® product in Chile, with potential expansion into other countries and regions of the South American market.\n\n \n \n \n \n \n \n\n \nDr. Neil J. Campbell, Marizyme's CEO, President and Board Member, said, \"The agreement with Abdera in Chile is both strategic and tactical to set up a market channel, KOL establishment for the South American market and customer support for Marizyme's product line starting with DuraGraft and has the potential to follow on with future platform products.\" \n\"We are excited to partner with Marizyme and bring this pivotal product DuraGraft to the Chilean health care market,\" said Konrad Ziller, Managing Director for Abdera.  \"DuraGraft will enhance coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction, providing better patient care, and potentially lowering the impact on the overall cost of health care in CABG procedures.\" \nAbout Abdera, Inc.\nAbdera Financial, Inc. is a Chile based distributor with access to the Chilean market to supply and distribute health care and life science products. Abdera has a long and established track record in the successful certification, distribution and marketing of medical and health care products.  \nAbout Marizyme, Inc.\nMarizyme is an integrated life sciences c...